Data / Form D filings / VYNE Therapeutics Inc.
VYNE Therapeutics Inc.: Form D filings
VYNE Therapeutics Inc., a biotechnology company in Bridgewater, NJ, filed 4 Form D notices with the SEC between 2013 and 2023. The latest, on November 16, 2023, reports $88.2 million sold of a $88.2 million offering to 19 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 685 ROUTE 202/206 N., SUITE 301, Bridgewater, NJ, 08807
- Phone
- (800) 775-7936
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1566044
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 16, 2023 | New notice | $88,151,508 | $88,151,508 | 19 | Nov 1, 2023 | sec.gov | |
| Nov 18, 2022 | New notice | $300,000 | $300,000 | 1 | Nov 14, 2022 | sec.gov | |
| Jul 28, 2017 | New notice | $50,500,001 | $50,500,001 | 11 | Jul 14, 2017 | sec.gov | |
| Jan 7, 2013 | New notice | $15,000,000 | $500,000 | $14,500,000 | 1 | Dec 21, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| SHARON BARBARI | Director | |
| MUTYA HARSCH | Executive Officer | |
| TYLER ZERONDA | Executive Officer | |
| DAVID DOMZALSKI | Executive Officer, Director | |
| ELISABETH SANDOVAL | Director | |
| PATRICK LEPORE | Director | |
| STEVEN BASTA | Director | |
| IAIN STUART | Executive Officer | |
| ANTHONY BRUNO | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Nov 13, 2023 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what VYNE Therapeutics Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.